Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Kyverna announced that the FDA granted RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) and confirmed it is on track to complete a rolling BLA submission for stiff person syndrome in Q4 2026. Financial results showed cash and marketable securities of $199.4 million as of June 30, 2026, which is expected to fund operations into 2028; Q2 net loss was $38.3 million with R&D expenses of $24.8 million.
Key figures
- Drug Name
- miv-cel
- Cash
- $199.4 million
- Net loss
- $38.3 million
- Ga expenses
- $14.8 million
- Rd expenses
- $24.8 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.